Physician
Stefanescu Sturz, Ionut
Stefanescu Sturz, Ionut was paid $513K by Medicaid between Dec 2019 and Dec 2024, across 15 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 38% of everything it billed.
33Billing provider infoSTEFANESCU STURZ, IONUT
HAZARD, KY 41701
HAZARD, KY 41701
33aNPI1124023973assigned 06/17/2005
33bProvider typeInternal Medicine Physician
28Total paid$513K
24GClaims16,118
24DCodes billed15
24AFirst – last monthDec 2019 – Dec 2024
Compared with peers
Next to other Internal Medicine Physician providers in Kentucky
Rank by total paid#54 of 231
Median peer was paid$77K
This provider vs. median6.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 14 | $129.68 | |
| 2020 | 2,875 | $124K | |
| 2021 | 3,631 | $117K | |
| 2022 | 3,749 | $98K | |
| 2023 | 3,212 | $93K | |
| 2024incomplete | 2,637 | $81K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 38% | 7,448 | 6,264 | $197K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 18% | 633 | 604 | $94K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 16% | 3,263 | 2,833 | $84K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 11% | 700 | 661 | $54K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 9.5% | 1,243 | 1,052 | $48K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 3.3% | 773 | 715 | $17K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 2.1% | 980 | 919 | $11K |
| 72131 | 1.5% | 42 | 42 | $8K | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 172 | 153 | $15.10 |
| 36415 | Collection of venous blood by venipuncture | <1% | 88 | 73 | $8.45 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | <1% | 220 | 164 | $0.19 |
| G9583 | Patients prescribed opiates for longer than six weeks | 0% | 215 | 161 | $0.00 |
3 more codes
| G9578 | Documentation of signed opioid treatment agreement at least once during opioid therapy | 0% | 219 | $0.00 |
| G8730 | Pain assessment documented as positive using a standardized tool and a follow-up plan is documented | 0% | 91 | $0.00 |
| G9562 | Patients who had a follow-up evaluation conducted at least every three months during opioid therapy | 0% | 31 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.